Stem Cell Therapy in PAD

European Journal of Vascular and Endovascular Surgery

Volumn 39, Issue SUPPL. 1, 2010, Pages

  Sprengers, R W ^a,b   Moll, F L ^a   Verhaar, M C ^b  

^a Department of Vascular Surgery ^*  (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Critical limb ischaemia; Peripheral arterial disease; Stem cell therapy

Indexed keywords

AMPUTATION; ARTICLE; CELL THERAPY; CLINICAL FEATURE; CLINICAL TRIAL; HUMAN; LIMB ISCHEMIA; MEDICAL RESEARCH; PERIPHERAL ISCHEMIA; PRIORITY JOURNAL; REVASCULARIZATION; STEM CELL TRANSPLANTATION;

ARTERIAL OCCLUSIVE DISEASES; CRITICAL ILLNESS; EXTREMITIES; HUMANS; ISCHEMIA; LIMB SALVAGE; NEOVASCULARIZATION, PHYSIOLOGIC; PATIENT SELECTION; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

EID: 77949301039     PISSN: 10785884     EISSN: 15322165     Source Type: Journal    
DOI: 10.1016/j.ejvs.2009.12.001     Document Type: Article

References (53)

1. Norgren L., Hiatt W.R., Dormandy J.A., Nehler M.R., Harris K.A., Fowkes F.G., Bell K., et al. Inter-society consensus for the management of peripheral arterial disease (TASC II). Eur J Vasc Endovasc Surg 33 Suppl 1 (2007) S1-75
2. Hirsch A.T., Criqui M.H., Treat-Jacobson D., Regensteiner J.G., Creager M.A., Olin J.W., et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 286 (2001) 1317-1324
3. Hankey G.J. Vascular disease of the heart, brain and limbs: new insights into a looming epidemic. Lancet 366 (2005) 1753-1754
4. Steg P.G., Bhatt D.L., Wilson P.W., D'Agostino Sr. R., Ohman E.M., Rother J., et al. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA 297 (2007) 1197-1206
5. Sprengers R.W., Janssen K.J.M., Moll F.L., Verhaar M.C., and Van der Graaf Y. Prediction rule for cardiovascular events and mortality in peripheral arterial disease patients: data from the prospective Second Manifestations of ARTerial disease (SMART) cohort study. J Vasc Surg 50 6 (2009 Dec) 1369-1376
6. Dormandy J., Heeck L., and Vig S. Predicting which patients will develop chronic critical leg ischemia. Semin Vasc Surg 12 (1999) 138-141
7. Gillum R.F. Peripheral arterial occlusive disease of the extremities in the United States: hospitalization and mortality. Am Heart J 120 (1990) 1414-1418
8. Albers M., Fratezi A.C., and De L.N. Assessment of quality of life of patients with severe ischemia as a result of infrainguinal arterial occlusive disease. J Vasc Surg 16 (1992) 54-59
9. Perifeer arterieel vaatlijden. In: Hart- en vaatziekten in Nederland 2003, cijfers over ziekte en sterfte. Den Haag: Nederlandse Hartstichting; 2003:21-52.
10. Murphy T.P. Medical outcomes studies in peripheral vascular disease. J Vasc Interv Radiol 9 (1998) 879-889
11. Hirsch A.T., Haskal Z.J., Hertzer N.R., Bakal C.W., Creager M.A., Halperin J.L., et al. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation 113 (2006) e463-e654
12. Landry G.J. Functional outcome of critical limb ischemia. J Vasc Surg 45 Suppl A (2007) A141-A148
13. Sprengers R.W., Lips D.J., Bemelman M., Verhaar M.C., and Moll F.L. Lower leg amputation due to critical limb ischaemia: morbidity, mortality and rehabilitation potential. Ned Tijdschr Geneeskd 151 (2007) 2185-2191
14. Second European Consensus Document on chronic critical leg ischemia. Circulation 84 (1991) IV1-26
15. Guidelines for percutaneous transluminal angioplasty. Standards of Practice Committee of the Society of Cardiovascular and Interventional Radiology. Radiology 177 (1990) 619-626
16. Valentine R.J., Myers S.I., Inman M.H., Roberts J.R., and Clagett G.P. Late outcome of amputees with premature atherosclerosis. Surgery 119 (1996) 487-493
17. Hiatt W.R. Medical treatment of peripheral arterial disease and claudication. N Engl J Med 344 (2001) 1608-1621
18. Rajagopalan S., Mohler III E.R., Lederman R.J., Mendelsohn F.O., Saucedo J.F., Goldman C.K., et al. Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication. Circulation 108 (2003) 1933-1938
19. Lederman R.J., Mendelsohn F.O., Anderson R.D., Saucedo J.F., Tenaglia A.N., Hermiller J.B., et al. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial. Lancet 359 (2002) 2053-2058
20. Sprengers R.W., Verhaar M.C., and Moll F.L. Growth factor and cell therapy in patients with critical limb ischemia. In: Bosiers M., and Schneider P. (Eds). Critical limb ischemia (2009), Informa Healthcare USA, Inc., New York 302-320
21. Simons M., and Ware J.A. Therapeutic angiogenesis in cardiovascular disease. Nat Rev Drug Discov 2 (2003) 863-871
22. Rajagopalan S., Olin J., Deitcher S., Pieczek A., Laird J., Grossman P.M., et al. Use of a constitutively active hypoxia-inducible factor-1alpha transgene as a therapeutic strategy in no-option critical limb ischemia patients: phase I dose-escalation experience. Circulation 115 (2007) 1234-1243
23. Asahara T., Murohara T., Sullivan A., Silver M., van der Zee R., Li T., et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 275 (1997) 964-967
24. Asahara T., Masuda H., Takahashi T., Kalka C., Pastore C., Silver M., et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res 85 (1999) 221-228
25. Takahashi T., Kalka C., Masuda H., Chen D., Silver M., Kearney M., et al. Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat Med 5 (1999) 434-438
26. Crosby J.R., Kaminski W.E., Schatteman G., Martin P.J., Raines E.W., Seifert R.A., et al. Endothelial cells of hematopoietic origin make a significant contribution to adult blood vessel formation. Circ Res 87 (2000) 728-730
27. Capla J.M., Ceradini D.J., Tepper O.M., Callaghan M.J., Bhatt K.A., Galiano R.D., et al. Skin graft vascularization involves precisely regulated regression and replacement of endothelial cells through both angiogenesis and vasculogenesis. Plast Reconstr Surg 117 (2006) 836-844
28. Shi Q., Rafii S., Wu M.H., Wijelath E.S., Yu C., Ishida A., et al. Evidence for circulating bone marrow-derived endothelial cells. Blood 92 (1998) 362-367
29. Shintani S., Murohara T., Ikeda H., Ueno T., Honma T., Katoh A., et al. Mobilization of endothelial progenitor cells in patients with acute myocardial infarction. Circulation 103 (2001) 2776-2779
30. Shintani S., Murohara T., Ikeda H., Ueno T., Sasaki K., Duan J., et al. Augmentation of postnatal neovascularization with autologous bone marrow transplantation. Circulation 103 (2001) 897-903
31. Kamihata H., Matsubara H., Nishiue T., Fujiyama S., Tsutsumi Y., Ozono R., et al. Implantation of bone marrow mononuclear cells into ischemic myocardium enhances collateral perfusion and regional function via side supply of angioblasts, angiogenic ligands, and cytokines. Circulation 104 (2001) 1046-1052
32. Sprengers R.W., Lips D.J., Moll F.L., and Verhaar M.C. Progenitor cell therapy in patients with critical limb ischemia without surgical options. Ann Surg 247 (2008) 411-420
33. Sprengers RW, Moll FL, Mali WPTM, Doevendans PA, Van der Graaf Y, Schutgens REG, et-al,. Repeated intra-arterial infusion of autologous bone marrow-derived mononuclear cells in patients with critical limb ischemia: rationale and design of the JUVENTAS Trial, unpublished work.
34. Vasa M., Fichtlscherer S., Aicher A., Adler K., Urbich C., Martin H., Aicher A., et al. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res 89 (2001) E1-E7
35. Fadini G.P., Sartore S., Albiero M., Baesso I., Murphy E., Menegolo M., et al. Number and function of endothelial progenitor cells as a marker of severity for diabetic vasculopathy. Arterioscler Thromb Vasc Biol 26 (2006) 2140-2146
36. Heeschen C., Lehmann R., Honold J., Assmus B., Aicher A., Walter D.H., et al. Profoundly reduced neovascularization capacity of bone marrow mononuclear cells derived from patients with chronic ischemic heart disease. Circulation 109 (2004) 1615-1622
37. Magri D., Fancher T.T., Fitzgerald T.N., Muto A., and Dardik A. Endothelial progenitor cells: a primer for vascular surgeons. Vascular 15 (2007) 384-394
38. Dzau V.J., Gnecchi M., Pachori A.S., Morello F., and Melo L.G. Therapeutic potential of endothelial progenitor cells in cardiovascular diseases. Hypertension 46 (2005) 7-18
39. Hill J.M., Zalos G., Halcox J.P., Schenke W.H., Waclawiw M.A., Quyyumi A.A., et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 348 (2003) 593-600
40. Assmus B., Urbich C., Aicher A., Hofmann W.K., Haendeler J., Rossig L., et al. HMG-CoA reductase inhibitors reduce senescence and increase proliferation of endothelial progenitor cells via regulation of cell cycle regulatory genes. Circ Res 92 (2003) 1049-1055
41. Gensch C., Clever Y.P., Werner C., Hanhoun M., Bohm M., and Laufs U. The PPAR-gamma agonist pioglitazone increases neoangiogenesis and prevents apoptosis of endothelial progenitor cells. Atherosclerosis 192 (2007) 67-74
42. George J., Goldstein E., Abashidze A., Wexler D., Hamed S., Shmilovich H., et al. Erythropoietin promotes endothelial progenitor cell proliferative and adhesive properties in a PI 3-kinase-dependent manner. Cardiovasc Res 68 (2005) 299-306
43. Honda A., Matsuura K., Fukushima N., Tsurumi Y., Kasanuki H., and Hagiwara N. Telmisartan induces proliferation of human endothelial progenitor cells via PPARgamma-dependent PI3K/Akt pathway. Atherosclerosis 205 (2009) 376-384
44. Dimmeler S., Aicher A., Vasa M., Mildner-Rihm C., Adler K., Tiemann M., et al. HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. J Clin Invest 108 (2001) 391-397
45. Llevadot J., Murasawa S., Kureishi Y., Uchida S., Masuda H., Kawamoto A., et al. HMG-CoA reductase inhibitor mobilizes bone marrow-derived endothelial progenitor cells. J Clin Invest 108 (2001) 399-405
46. Vasa M., Fichtlscherer S., Adler K., Aicher A., Martin H., Zeiher A.M., et al. Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease. Circulation 103 (2001) 2885-2890
47. Shantsila E., Watson T., and Lip G.Y. Endothelial progenitor cells in cardiovascular disorders. J Am Coll Cardiol 49 (2007) 741-752
48. Pistrosch F., Herbrig K., Oelschlaegel U., Richter S., Passauer J., Fischer S., et al. PPARgamma-agonist rosiglitazone increases number and migratory activity of cultured endothelial progenitor cells. Atherosclerosis 183 (2005) 163-167
49. Wang C.H., Ting M.K., Verma S., Kuo L.T., Yang N.I., Hsieh I.C., et al. Pioglitazone increases the numbers and improves the functional capacity of endothelial progenitor cells in patients with diabetes mellitus. Am Heart J 152 (2006) 1051-1058
50. Sasaki K., Heeschen C., Aicher A., Ziebart T., Honold J., Urbich C., et al. Ex vivo pre-treatment of bone marrow mononuclear cells with endothelial NO synthase enhancer AVE9488 enhances their functional activity for cell therapy. Proc Natl Acad Sci USA 103 (2006) 14537-14541
51. Rehman J., Li J., Orschell C.M., and March K.L. Peripheral blood "endothelial progenitor cells" are derived from monocyte/macrophages and secrete angiogenic growth factors. Circulation 107 (2003) 1164-1169
52. Kalka C., Masuda H., Takahashi T., Kalka-Moll W.M., Silver M., Kearney M., et al. Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization. Proc Natl Acad Sci USA 97 (2000) 3422-3427
53. Rouwkema J., Westerweel P.E., de Boer J., Verhaar M.C., and van Blitterswijk C.A. The use of endothelial progenitor cells for prevascularized bone tissue engineering. Tissue Eng Part A 15 (2009) 2015-2027